Literature DB >> 15640601

A prospective, randomized, double-blind crossover study on the use of 5% citrate lock versus 10% citrate lock in permanent hemodialysis catheters.

Gert Meeus1, Dirk R J Kuypers, Kathleen Claes, Pieter Evenepoel, Bart Maes, Yves Vanrenterghem.   

Abstract

Central venous catheters are used as permanent vascular access for chronic hemodialysis when construction of an arteriovenous fistula is not possible or contraindicated. We prospectively evaluated the efficacy and safety of a 5% citrate versus 10% citrate catheter lock for permanent single-lumen dialysis catheters in a double-blind, crossover study of 28 patients during 1,876 dialysis sessions. There was a slightly higher number of dialysis sessions with clot formation in the 5% citrate group; entirely attributable to the formation of small clots. There was no statistically significant difference in the formation of large clots, complete obstruction of the catheter or the need for urokinase between the 2 study groups. In view of the ongoing debate on the safety of high-concentration citrate catheter locks, we conclude that a 5% citrate lock is equally efficient in preventing catheter dysfunction compared with a 10% citrate lock and is therefore the preferred citrate catheter-locking solution.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15640601     DOI: 10.1159/000083203

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  6 in total

Review 1.  Vascular access in elderly patients with end-stage renal disease.

Authors:  Nikolaos Bessias; Kosmas I Paraskevas; Effie Tziviskou; Vassilios Andrikopoulos
Journal:  Int Urol Nephrol       Date:  2008-09-16       Impact factor: 2.370

Review 2.  Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease.

Authors:  Ying Wang; Jessica N Ivany; Vlado Perkovic; Martin P Gallagher; Mark Woodward; Meg J Jardine
Journal:  Cochrane Database Syst Rev       Date:  2016-04-04

3.  Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS).

Authors:  Jennifer M Macrae; Ivana Dojcinovic; Ognjenka Djurdjev; Beverly Jung; Steven Shalansky; Adeera Levin; Mercedeh Kiaii
Journal:  Clin J Am Soc Nephrol       Date:  2008-03       Impact factor: 8.237

Review 4.  Reevaluation of lock solutions for Central venous catheters in hemodialysis: a narrative review.

Authors:  Yiqin Wang; Xuefeng Sun
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

Review 5.  Antimicrobial lock solutions for preventing catheter-related infections in haemodialysis.

Authors:  Maria C Arechabala; Maria I Catoni; Juan Carlos Claro; Noelia P Rojas; Miriam E Rubio; Mario A Calvo; Luz M Letelier
Journal:  Cochrane Database Syst Rev       Date:  2018-04-03

6.  Microbial inactivation properties of a new antimicrobial/antithrombotic catheter lock solution (citrate/methylene blue/parabens).

Authors:  Janusz Steczko; Stephen R Ash; David E Nivens; Lloyd Brewer; Roland K Winger
Journal:  Nephrol Dial Transplant       Date:  2009-01-30       Impact factor: 5.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.